Cell Cycle Inhibitors: Wee1 Inhibitors
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Cell Cycle Inhibitors: Wee1 Inhibitors
Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
---|---|---|---|---|
Drugs in Clinical Development | ||||
NCT01357161 | II | Adavosertib, Carboplatin, Paclitaxel | A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer | Improved PFS with addition of AZD1775 Ada+CarboPt+Pac vs CarboPt+Pac: ORR: 81.4 vs 75.8% pub 2020 |
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
---|---|---|---|---|
Drugs in Clinical Development | ||||
NCT01164995 | II | Adavosertib, Carboplatin | Phase II Pharmacological Study With Wee-1 Inhibitor MK-1775 Combined With Carboplatin in Patients With p53 Mutated Epithelial Ovarian Cancer and Early Relapse (< 3 Months) or Progression During Standard First Line Treatment | Promising activity of adavosertib+carboplatin combination in TP53-mutated primary platinum resistant and platinum refractory ovarian cancer; a large proportion of responding patient had CCNE1 AMP ORR: 41% pub 2016, pub 2023 |
NCT02101775 | II | Adavosertib, Gemcitabine | A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers | Addition of adavosertib to gemzar improves ORR, PFS and OS Gem+Ada vs Gem: ORR: 25 vs 7% pub 2021 |
NCT02272790 | II | Adavosertib, Carboplatin | A Multicentre Phase II Study of Adavosertib Plus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Adavosertib+carboplatin shows efficacy in primary platinum resistant ovarian cancer with greatest benefit in patients receiving adavosertib weeks 1–3+carboplatin, but with increased hematologic toxicity
Ada week 1+CarboPt: Ada week 1-3+CarboPt pub 2022 |
NCT04516447 | I | Azenosertib, Carboplatin, Liposomal doxorubicin, Paclitaxel, Gemcitabine | A Phase 1b Study of ZN-c3 in Combination With Chemotherapy in Patients With Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer | Azenosertib (ZN-c3), combined with chemotherapy, is well-tolerated and demonstrates clinical activity in patients with Pt-R or Pt-Rf OC Aze+CarboPt: Aze+Pac: Aze+Gem: (n=13) Aze+PLD: abs Jun 2023 and poster |
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
---|---|---|---|---|
Drugs in Clinical Development | ||||
NCT03579316 | II | Adavosertib, Olaparib | EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition | Adavosertib alone and in combination with olaparib demonstrates efficacy in patients with PARPi-resistant OC irrespective of BRCA status Ada+Ola vs Ada: ORR: 29 vs 23%; DoR: 6.4 vs 5.5 months: DCR (4 months): 89 vs 63%; PFS: 6.8 vs 5.5 months BRCA MUT: abs Jun 2021 and presentation |
NCT02482311 | Ib | Adavosertib | A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours | Adavosertib is well tolerated and shows preliminary antitumor activity. No clear correlation between genomic profile and clinical response 30 OC BRCA MUT after PARPi failure: 16 OC BRCA WT: pub 2023 |
NCT02511795 | Ib | Adavosertib, Olaparib | A Phase Ib Study of AZD1775 and Olaparib in Patients With Refractory Solid Tumours | Adavosertib+olaparib shows anti-tumor activity in ovarian cancer, particularly at the twice daily (BID) schedule ORR: 15% abs Apr 2019 and poster |